ClinicalTrials.gg
CompletedNCT04702737DeLLpro-300Updated Sep 12, 2025Results posted

A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer

A Phase 1 interventional study of Tarlatamab in Neuroendocrine Prostate Cancer, sponsored by Amgen. Completed at 21 sites in 9 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-12.

Sponsored by Amgen · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
41
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Prostatic Neoplasms by Amgen — 4 open to participants now, 7 under way, 2 of them phase 3. Prostatic Neoplasms · Amgen.

Enrollment
16th of 21
41 · median 64
Started
2021
with 1 other
Phase 1
9 of 23
3 open now
Registered
16th of 23
by date

Among the 23 studies in Prostatic Neoplasms by Amgen, this one is the 16th largest by enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2021, is one of 9 in phase 1, and was the 16th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

4 of the 23 studies in Prostatic Neoplasms by Amgen are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Prostatic Neoplasms by Amgen, or all of them as a file.
02

Study summary

To evaluate the safety and tolerability of Tarlatamab and will determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).

03

Conditions studied

  • Neuroendocrine Prostate Cancer

Browse trials for

Keywords

  • De novo or treatment emergent neuroendocrine prostate cancer
  • Non-canonical Notch ligand
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria (Part 1: Dose Exploration and Part 2: Dose Expansion):

  • Participant has provided prior to initiation of any study specific activities/procedures.
  • Men aged ≥ 18 years at time of signing the informed consent.
  • de novo or treatment-emergent neuroendocrine prostate cancer (NEPC) defined by histology, immunohistochemistry, or genomic analyses of baseline tumor tissue (by local assessment) or circulating tumor DNA (ctDNA) (by local assessment) as per protocol
  • At least 1 line of prior systemic treatment per protocol.
  • Participants with treatment-emergent NEPC or de novo NEPC with histologic evidence of prostate cancer with neuroendocrine differentiation without a history of bilateral orchiectomy are required to remain on luteinizing hormone-releasing hormone (LHRH) analogue therapy during the course of protocol therapy
  • per (RECIST) 1.1 per Prostate Cancer Working Group 3 (PCWG3) modifications
  • (ECOG) Performance Status of ≤ 2
  • Participants with treated are eligible provided they meet defined criteria
  • Adequate organ function as defined in protocol

Exclusion Criteria (Part 1: Dose Exploration and Part 2: Dose Expansion):

  • History of other within the past 2 years, with exceptions:

    • Malignancy treated with curative intent and with no known active disease present for ≥ 2 years before enrollment and felt to be at low risk for recurrence by the treating physician
    • Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
    • Adequately treated non-muscle invasive urothelial carcinoma
  • History or presence of hematological malignancies unless curatively treated with no evidence of disease ≥ 2 years
  • Untreated or symptomatic brain metastases and
  • Anti-tumor therapy within 28 days of study day 1; concurrent use of hormone deprivation therapy for hormone prostate cancer is permitted; participants on a stable bisphosphonate or denosumab prior to study day 1 are eligible

Exceptions:

  • Participants who received conventional chemotherapy are eligible if at least 14 days have elapsed and if all treatment-related toxicities have resolved to Grade ≤ 1
  • Prior palliative radiotherapy must have been completed at least 7 days before the first dose of tarlatamab
  • Participants who received androgen signaling inhibitor are eligible if at least 14 days have elapsed and if all treatment-related toxicity has been resolved to Grade ≤ 1

    • Has a diagnosis of immunodeficiency or is receiving systemic therapy or any other form of therapy within 7 days prior study day 1
    • Active disease requiring systemic treatment within the past 2 years
    • Known positive test for (HIV) or hepatitis
    • Unresolved toxicities from prior anti-tumor therapy, defined as not having resolved to (CTCAE) version 4.0 grade 0 or 1 (with the exception of alopecia or toxicities that are stable and well-controlled)
    • History of hypophysitis or pituitary dysfunction
    • Has evidence of interstitial lung disease or active, non-infectious pneumonitis.
    • Participants on prior delta-like ligand 3 (DLL3)-targeted therapy may be eligible if discussed with Amgen Medical Monitor prior to enrollment
    • Evidence of severe acute respiratory syndrome coronavirus 2 (SARS-COV2) infection unless agreed upon with Medical Monitor and with no acute symptoms of coronavirus disease 2019 (COVID19) disease within 14 days prior to first dose of product (counted from day of positive test for asymptomatic participants).
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Part 1: Dose Exploration

    The maximum tolerated dose (MTD) will be estimated using isotonic regression (Ji et al, 2010). The recommended phase 2 dose (RP2D) may be identified based on emerging safety data prior to reaching an MTD.

    Drug: Tarlatamab

  • Experimental
    Part 2: Dose Expansion

    Participants will receive the RP2D/MTD identified in Part 1 (dose exploration) of the study.

    Drug: Tarlatamab

Interventions

  • Tarlatamab will be administered as an intravenous (IV) infusion.

    Also known as: AMG 757

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experienced One or More Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant irrespective of a causal relationship with the study treatment. A TEAE was defined as an AE starting on or after the first dose of tarlatamab, and up to and including 47 days after the last dose of tarlatamab excluding the events reported after End of Study date. Clinically significant changes from baseline in vital signs, 12-lead electrocardiograms (ECGs) and clinical laboratory tests were also reported as TEAEs.

    Time frame: Up to approximately 3 years

  2. Number of Participants Who Experienced One or More Treatment-related Adverse Events (TRAE)

    A TRAE was defined as a TEAE that per investigator review had a reasonable possibility of being caused by tarlatamab. Clinically significant changes from baseline in vital signs, 12-lead ECGs and clinical laboratory tests were also reported as TEAEs.

    Time frame: Up to approximately 3 years

  3. Number of Participants Who Experienced Dose Limiting Toxicities (DLTs)

    A DLT was defined as any qualifying toxicity that was at least possibly related to tarlatamab with an onset within the first 28 days following first dose with either of the following criteria: 1. Grade 3 adverse event lasting more than 3 days (with the exception of fatigue and Grade 3 non-febrile neutropenia that improved to ≤ Grade 1 within 3 weeks including the use of growth factor support per neutropenia management guidelines); 2. ≥ Grade 4 adverse event regardless of duration (with the exception of grade 4 non-febrile neutropenia lasting less than or equal to 7 days including the use of growth factor support per neutropenia management guidelines).

    Time frame: Up to 28 days

Secondary outcomes

  1. Objective Response Rate (ORR)

    OR was assessed per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 with Prostate Cancer Working Group 3 (PCWG3) modifications. OR was defined as best overall response of partial response (PR) or complete response (CR) per RECIST 1.1, confirmed by an assessment at least 4 weeks later. Participants who did not experience a PR/CR or did not have any follow-up tumor assessments were regarded as non-responders. ORR was defined as the percentage of participants with a best overall response of confirmed CR or PR per RECIST 1.1. The percentage of participants with an OR was summarized along with the Clopper-Pearson (Clopper and Pearson, 1934) exact 95% confidence interval (CI). The result reported was evaluated by central reviewer assessment.

    Time frame: Up to approximately 3 years

  2. Duration of Response (DOR)

    DOR was defined as the time from the date of an initial objective response to the earlier of progressive disease or death for participants with an objective response per RECIST 1.1. DOR was assessed per RECIST 1.1 with PCWG3 modifications. The distribution of DOR was summarized using the Kaplan-Meier (KM) method with CI calculated using the Brookmeyer and Crowley (Brookmeyer and Crowley, 1982) method. The result reported was evaluated by central reviewer assessment.

    Time frame: Up to approximately 3 years

  3. Radiographic Progression-free Survival (PFS)

    Radiographic PFS was defined as the interval from the first dose of tarlatamab to the earlier of a radiographic progression or death from any cause. Radiographic PFS was assessed per RECIST 1.1 with PCWG3 modifications. The distribution of radiographic PFS was summarized using the KM method with CI calculated using the Brookmeyer and Crowley (Brookmeyer and Crowley, 1982) method. The result reported was evaluated by central reviewer assessment.

    Time frame: Up to approximately 3 years

  4. Overall Survival (OS)

    OS was defined as the time from the start of treatment until event of death due to any cause. The distribution of OS was summarized using the KM method with CI calculated using the Brookmeyer and Crowley (Brookmeyer and Crowley, 1982) method.

    Time frame: Up to approximately 3 years

  5. Disease Control Rate (DCR)

    DCR was defined as the percentage of participants with a best overall response of confirmed response (CR/PR) or stable disease (SD) as per RECIST 1.1. The DCR was assessed per RECIST 1.1. The percentage of participants with disease control with corresponding exact 95% CI was calculated using the Clopper-Pearson (Clopper and Pearson, 1934) method. The result reported was evaluated by central reviewer assessment.

    Time frame: Up to approximately 3 years

  6. Maximum Serum Concentration (Cmax) of Tarlatamab

    Pharmacokinetic (PK) parameters of tarlatamab were determined from the time concentration profile using standard non-compartmental approaches and considering the profile over the complete sampling interval.

    Time frame: Cycle 2 Day 1 and Day 15: Predose, end of infusion (EOI), 2, 6, 24, 48, 96 and 168 hours after EOI

  7. Tarlatamab Concentration at the End of a Dosing Interval or Before Planned Next Dose (Ctrough)

    PK parameters of tarlatamab were determined from the time concentration profile using standard non-compartmental approaches and considering the profile over the complete sampling interval. The result for this endpoint is given for cycle 2 only.

    Time frame: Cycle 2 Day 15: Predose

  8. Area Under the Concentration-time Curve Over the Dosing Interval From Time 0 to 336 Hours (AUC336) of Tarlatamab

    PK parameters of tarlatamab were determined from the time concentration profile using standard non-compartmental approaches and considering the profile over the complete sampling interval. The result for this endpoint is given for cycle 2 only.

    Time frame: Cycle 2 Day 1 and Day 15: Predose, EOI, 2, 6, 24, 48, 96, 168, and 336 hours after EOI

  9. Terminal Phase Elimination Half-life (t1/2,z) of Tarlatamab

    PK parameters of tarlatamab were determined from the time concentration profile using standard non-compartmental approaches and considering the profile over the complete sampling interval. The result for this endpoint is given for cycle 2 only.

    Time frame: Cycle 2 Day 15: Predose, EOI, 2, 6, 24, 48, 96 and 168 hours after EOI

07

Results

Posted Sep 12, 2025

Participant flow

A total of 41 participants were enrolled into this study in the United States, Australia, Austria, Belgium, France, Japan, Netherlands, and Spain between June 2021 and July 2024.

Participant flow — Overall Study
MilestoneTarlatamab Dose Expansion
Started41
Participants who received treatment40
Completed1
Not completed40
Withdrew: Decision by sponsor1
Withdrew: Withdrawal of consent from study3
Withdrew: Lost to follow-up1
Withdrew: Death35

Outcome measures

PrimaryNumber of Participants Who Experienced One or More Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant irrespective of a causal relationship with the study treatment. A TEAE was defined as an AE starting on or after the first dose of tarlatamab, and up to and including 47 days after the last dose of tarlatamab excluding the events reported after End of Study date. Clinically significant changes from baseline in vital signs, 12-lead electrocardiograms (ECGs) and clinical laboratory tests were also reported as TEAEs.

Time frame:
Up to approximately 3 years
Reported as:
Count of participants · Participants
Number of Participants Who Experienced One or More Treatment-emergent Adverse Events (TEAEs)
ParticipantsTarlatamab Dose Expansion
Number of Participants Who Experienced One or More Treatment-emergent Adverse Events (TEAEs)40
PrimaryNumber of Participants Who Experienced One or More Treatment-related Adverse Events (TRAE)

A TRAE was defined as a TEAE that per investigator review had a reasonable possibility of being caused by tarlatamab. Clinically significant changes from baseline in vital signs, 12-lead ECGs and clinical laboratory tests were also reported as TEAEs.

Time frame:
Up to approximately 3 years
Reported as:
Count of participants · Participants
Number of Participants Who Experienced One or More Treatment-related Adverse Events (TRAE)
ParticipantsTarlatamab Dose Expansion
Number of Participants Who Experienced One or More Treatment-related Adverse Events (TRAE)40
PrimaryNumber of Participants Who Experienced Dose Limiting Toxicities (DLTs)

A DLT was defined as any qualifying toxicity that was at least possibly related to tarlatamab with an onset within the first 28 days following first dose with either of the following criteria: 1. Grade 3 adverse event lasting more than 3 days (with the exception of fatigue and Grade 3 non-febrile neutropenia that improved to ≤ Grade 1 within 3 weeks including the use of growth factor support per neutropenia management guidelines); 2. ≥ Grade 4 adverse event regardless of duration (with the exception of grade 4 non-febrile neutropenia lasting less than or equal to 7 days including the use of growth factor support per neutropenia management guidelines).

Time frame:
Up to 28 days
Reported as:
Count of participants · Participants
Number of Participants Who Experienced Dose Limiting Toxicities (DLTs)
ParticipantsTarlatamab Dose Expansion
Number of Participants Who Experienced Dose Limiting Toxicities (DLTs)1
SecondaryObjective Response Rate (ORR)

OR was assessed per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 with Prostate Cancer Working Group 3 (PCWG3) modifications. OR was defined as best overall response of partial response (PR) or complete response (CR) per RECIST 1.1, confirmed by an assessment at least 4 weeks later. Participants who did not experience a PR/CR or did not have any follow-up tumor assessments were regarded as non-responders. ORR was defined as the percentage of participants with a best overall response of confirmed CR or PR per RECIST 1.1. The percentage of participants with an OR was summarized along with the Clopper-Pearson (Clopper and Pearson, 1934) exact 95% confidence interval (CI). The result reported was evaluated by central reviewer assessment.

Time frame:
Up to approximately 3 years
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsTarlatamab Dose Expansion
Objective Response Rate (ORR)12.0 (2.5 to 31.2)
SecondaryDuration of Response (DOR)

DOR was defined as the time from the date of an initial objective response to the earlier of progressive disease or death for participants with an objective response per RECIST 1.1. DOR was assessed per RECIST 1.1 with PCWG3 modifications. The distribution of DOR was summarized using the Kaplan-Meier (KM) method with CI calculated using the Brookmeyer and Crowley (Brookmeyer and Crowley, 1982) method. The result reported was evaluated by central reviewer assessment.

Time frame:
Up to approximately 3 years
Reported as:
Median · months
Duration of Response (DOR)
monthsTarlatamab Dose Expansion
Duration of Response (DOR)NA (NA to NA)
SecondaryRadiographic Progression-free Survival (PFS)

Radiographic PFS was defined as the interval from the first dose of tarlatamab to the earlier of a radiographic progression or death from any cause. Radiographic PFS was assessed per RECIST 1.1 with PCWG3 modifications. The distribution of radiographic PFS was summarized using the KM method with CI calculated using the Brookmeyer and Crowley (Brookmeyer and Crowley, 1982) method. The result reported was evaluated by central reviewer assessment.

Time frame:
Up to approximately 3 years
Reported as:
Median · months
Radiographic Progression-free Survival (PFS)
monthsTarlatamab Dose Expansion
Radiographic Progression-free Survival (PFS)2.1 (1.8 to 3.8)
SecondaryOverall Survival (OS)

OS was defined as the time from the start of treatment until event of death due to any cause. The distribution of OS was summarized using the KM method with CI calculated using the Brookmeyer and Crowley (Brookmeyer and Crowley, 1982) method.

Time frame:
Up to approximately 3 years
Reported as:
Median · months
Overall Survival (OS)
monthsTarlatamab Dose Expansion
Overall Survival (OS)7.9 (4.4 to 13.2)
SecondaryDisease Control Rate (DCR)

DCR was defined as the percentage of participants with a best overall response of confirmed response (CR/PR) or stable disease (SD) as per RECIST 1.1. The DCR was assessed per RECIST 1.1. The percentage of participants with disease control with corresponding exact 95% CI was calculated using the Clopper-Pearson (Clopper and Pearson, 1934) method. The result reported was evaluated by central reviewer assessment.

Time frame:
Up to approximately 3 years
Reported as:
Number · percentage of participants
Disease Control Rate (DCR)
percentage of participantsTarlatamab Dose Expansion
Disease Control Rate (DCR)36.0 (18.0 to 57.5)
SecondaryMaximum Serum Concentration (Cmax) of Tarlatamab

Pharmacokinetic (PK) parameters of tarlatamab were determined from the time concentration profile using standard non-compartmental approaches and considering the profile over the complete sampling interval.

Time frame:
Cycle 2 Day 1 and Day 15: Predose, end of infusion (EOI), 2, 6, 24, 48, 96 and 168 hours after EOI
Reported as:
Geometric mean · μg/mL
Maximum Serum Concentration (Cmax) of Tarlatamab
μg/mLTarlatamab Dose Expansion
Cycle 2 Day 131.1 ± 26
Cycle 2 Day 1531.7 ± 19
SecondaryTarlatamab Concentration at the End of a Dosing Interval or Before Planned Next Dose (Ctrough)

PK parameters of tarlatamab were determined from the time concentration profile using standard non-compartmental approaches and considering the profile over the complete sampling interval. The result for this endpoint is given for cycle 2 only.

Time frame:
Cycle 2 Day 15: Predose
Reported as:
Geometric mean · μg/mL
Tarlatamab Concentration at the End of a Dosing Interval or Before Planned Next Dose (Ctrough)
μg/mLTarlatamab Dose Expansion
Tarlatamab Concentration at the End of a Dosing Interval or Before Planned Next Dose (Ctrough)5.36 ± 36
SecondaryArea Under the Concentration-time Curve Over the Dosing Interval From Time 0 to 336 Hours (AUC336) of Tarlatamab

PK parameters of tarlatamab were determined from the time concentration profile using standard non-compartmental approaches and considering the profile over the complete sampling interval. The result for this endpoint is given for cycle 2 only.

Time frame:
Cycle 2 Day 1 and Day 15: Predose, EOI, 2, 6, 24, 48, 96, 168, and 336 hours after EOI
Reported as:
Geometric mean · hr*μg/mL
Area Under the Concentration-time Curve Over the Dosing Interval From Time 0 to 336 Hours (AUC336) of Tarlatamab
hr*μg/mLTarlatamab Dose Expansion
Cycle 2 Day 14010 ± 28
Cycle 2 Day 154260 ± 26
SecondaryTerminal Phase Elimination Half-life (t1/2,z) of Tarlatamab

PK parameters of tarlatamab were determined from the time concentration profile using standard non-compartmental approaches and considering the profile over the complete sampling interval. The result for this endpoint is given for cycle 2 only.

Time frame:
Cycle 2 Day 15: Predose, EOI, 2, 6, 24, 48, 96 and 168 hours after EOI
Reported as:
Geometric mean · days
Terminal Phase Elimination Half-life (t1/2,z) of Tarlatamab
daysTarlatamab Dose Expansion
Terminal Phase Elimination Half-life (t1/2,z) of Tarlatamab7.23 ± 33

Adverse events

Collected over Death - From enrollment until End of Study (EOS); Median (min, max) was 6.7 (0.1, 37.4) months. TEAE - from 1st study drug until min(last dose + 65 days, EOS); Median (min, max) duration was 3.6 (1.1, 37.3) months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tarlatamab Dose Expansion35/41 (85.4%)27/40 (67.5%)40/40 (100%)
Most frequent serious events
Showing 10 of 41
Most frequent serious events
EventTarlatamab Dose Expansion
Cytokine release syndromeImmune system disorders9/40
Neuroendocrine carcinoma of prostateNeoplasms benign, malignant and unspecified (incl cysts and polyps)5/40
FatigueGeneral disorders4/40
Prostate cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)4/40
Acute kidney injuryRenal and urinary disorders3/40
SepsisInfections and infestations2/40
Neuroendocrine cancer of the prostate metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/40
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/40
Atrial flutterCardiac disorders1/40
Supraventricular tachycardiaCardiac disorders1/40
Most frequent other events
Showing 10 of 74
Most frequent other events
EventTarlatamab Dose Expansion
Cytokine release syndromeImmune system disorders26/40
Decreased appetiteMetabolism and nutrition disorders20/40
ConstipationGastrointestinal disorders18/40
DysgeusiaNervous system disorders17/40
FatigueGeneral disorders16/40
PyrexiaGeneral disorders16/40
AnaemiaBlood and lymphatic system disorders14/40
NauseaGastrointestinal disorders13/40
VomitingGastrointestinal disorders11/40
HeadacheNervous system disorders10/40

Baseline characteristics

Safety Analysis Set: all participants who were enrolled and received at least 1 dose of tarlatamab.

Age, Continuous
Age, Continuous(years)Tarlatamab Dose Expansion
Mean64 ± 9.1
Sex: Female, Male
Sex: Female, Male(Participants)Tarlatamab Dose Expansion
Female0
Male40
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Tarlatamab Dose Expansion
Hispanic or Latino2
Not Hispanic or Latino27
Unknown or Not Reported11
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Tarlatamab Dose Expansion
American Indian or Alaska Native0
Asian3
Native Hawaiian or Other Pacific Islander0
Black or African American0
White29
More than one race0
Unknown or Not Reported8
08

Study locations

21 sites
  • Mayo Clinic Arizona
    Phoenix, Arizona 85054, United States
  • University of California at San Francisco Helen Diller Family Comprehensive Cancer Center
    San Francisco, California 94158, United States
  • Winship Cancer Institute of Emory University
    Atlanta, Georgia 30322, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Community Health Network MD Anderson Cancer Center - North
    Indianapolis, Indiana 46250, United States
  • Washington University
    St Louis, Missouri 63110-1093, United States
  • Weill Cornell Medical College
    New York, New York 10021, United States
  • Wake Forest University Health Sciences
    Winston-Salem, North Carolina 27103, United States
  • The Ohio State University
    Columbus, Ohio 43210, United States
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Chris OBrien Lifehouse
    Camperdown, New South Wales 2050, Australia
  • Peter MacCallum Cancer Centre
    Melbourne, Victoria 3000, Australia
  • Medizinische Universitaet Graz
    Graz, 8036, Austria
  • Ordensklinikum Linz Elisabethinen
    Linz, 4020, Austria
  • Landeskrankenhaus Salzburg
    Salzburg, 5020, Austria
  • Universitair Ziekenhuis Gent
    Ghent, 9000, Belgium
  • Gustave Roussy
    Villejuif, 94805, France
  • Keio University Hospital
    Shinjuku-ku, Tokyo 160-8582, Japan
  • Erasmus Medisch Centrum
    Rotterdam, 3015 GD, Netherlands
  • Hospital Clinic i Provincial de Barcelona
    Barcelona, Catalonia 08036, Spain
  • Royal Marsden Hospital
    Sutton, SM2 5PT, United Kingdom
09

References and documents

Publications

  • Aggarwal R, Rottey S, Bernard-Tessier A, Mellado B, Kosaka T, Stadler WM, Horvath L, Greil R, O'Neil B, Siddiqui BA, Bauernhofer T, Bilen MA, Eskens F, Sandhu S, Shaw C, Ju CH, Decato BE, Yu B, Aparicio A. Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study. Clin Cancer Res. 2025 Sep 15;31(18):3854-3863. doi: 10.1158/1078-0432.CCR-25-1211. PubMed 40689871 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Jul 2024, 37 months.

Results were first posted in Sep 2025, 1 year 1 month after primary completion.

Of 212 industry-sponsored phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's 37 months is close to that.

Counting every sponsor, half of 456 studies reached it within 43 months; a quarter within 23 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2021
First posted
Jan 11, 2021
StartActual
Jun 10, 2021
Primary completionActual
Jul 22, 2024
CompletionActual
Jul 22, 2024
Results first posted
Sep 12, 2025
Last update
Sep 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04702737
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jan 11, 2021
Start date
Jun 10, 2021
Primary completion
Jul 22, 2024
Completion
Jul 22, 2024
Results posted
Sep 12, 2025
Last update
Sep 12, 2025

Study contacts

MD
study director · Amgen

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AMG 757

Start the discussion